297 filings
Page 4 of 15
6-K
PRQR
ProQR Therapeutics N.V
16 Dec 21
ProQR Announces First Patients Dosed in Phase 2/3 Pivotal Trials of QR-421a for USH2A mediated Retinitis Pigmentosa
7:23am
6-K
PRQR
ProQR Therapeutics N.V
18 Nov 21
ProQR Announces Highlights from Analyst Event
4:25pm
6-K
PRQR
ProQR Therapeutics N.V
18 Nov 21
Current report (foreign)
11:46am
424B5
PRQR
ProQR Therapeutics N.V
17 Nov 21
Prospectus supplement for primary offering
4:47pm
424B5
PRQR
ProQR Therapeutics N.V
17 Nov 21
Prospectus supplement for primary offering
4:45pm
EFFECT
PRQR
ProQR Therapeutics N.V
17 Nov 21
Notice of effectiveness
12:15am
CORRESP
PRQR
ProQR Therapeutics N.V
12 Nov 21
Correspondence with SEC
12:00am
UPLOAD
PRQR
ProQR Therapeutics N.V
10 Nov 21
Letter from SEC
12:00am
S-8
PRQR
ProQR Therapeutics N.V
5 Nov 21
Registration of securities for employees
9:03am
F-3
PRQR
ProQR Therapeutics N.V
4 Nov 21
Shelf registration (foreign)
5:02pm
F-3
PRQR
ProQR Therapeutics N.V
4 Nov 21
Shelf registration (foreign)
4:58pm
6-K
PRQR
ProQR Therapeutics N.V
4 Nov 21
Current report (foreign)
7:30am
6-K
PRQR
ProQR Therapeutics N.V
4 Oct 21
ProQR Appoints Theresa Heggie as Chief Commercial Officer
8:21am
SC 13G
LLY
Lilly(Eli) & Co
10 Sep 21
ProQR Therapeutics / ELI LILLY & Co ownership change
1:03pm
6-K
PRQR
ProQR Therapeutics N.V
9 Sep 21
Current report (foreign)
8:01am
6-K
PRQR
ProQR Therapeutics N.V
8 Sep 21
ProQR Announces Axiomer® RNA Editing Licensing and Research Collaboration with Lilly
4:10pm
6-K
PRQR
ProQR Therapeutics N.V
5 Aug 21
Current report (foreign)
8:31am
6-K
PRQR
ProQR Therapeutics N.V
8 Jul 21
Current report (foreign)
4:40pm
6-K
PRQR
ProQR Therapeutics N.V
20 May 21
Current report (foreign)
4:31pm
6-K
PRQR
ProQR Therapeutics N.V
6 May 21
Current report (foreign)
7:16am